Balwinder Singh1, Ajay K Parsaik2, Michelle M Mielke3, Patricia J Erwin4, David S Knopman2, Ronald C Petersen5, Rosebud O Roberts5. 1. Department of Neurology, Mayo Clinic, Rochester, MN, USA Department of Clinical Neuroscience, University of North Dakota School of Medicine and Health Sciences, Fargo, ND, USA. 2. Department of Neurology, Mayo Clinic, Rochester, MN, USA. 3. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 4. Mayo Medical Libraries, Mayo Clinic, Rochester, MN, USA. 5. Department of Neurology, Mayo Clinic, Rochester, MN, USA Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Abstract
BACKGROUND/ OBJECTIVE: To conduct a systematic review of all studies to determine whether there is an association between the Mediterranean diet (MeDi) and cognitive impairment. METHODS: We conducted a comprehensive search of the major databases and hand-searched proceedings of major neurology, psychiatry, and dementia conferences through November 2012. Prospective cohort studies examining the MeDi with longitudinal follow-up of at least 1 year and reporting cognitive outcomes (mild cognitive impairment [MCI] or Alzheimer's disease [AD]) were included. The effect size was estimated as hazard-ratio (HR) with 95% confidence intervals (CIs) using the random-effects model. Heterogeneity was assessed using Cochran's Q-test and I2-statistic. RESULTS: Out of the 664 studies screened, five studies met eligibility criteria. Higher adherence to the MeDi was associated with reduced risk of MCI and AD. The subjects in the highest MeDi tertile had 33% less risk (adjusted HR = 0.67; 95% CI, 0.55-0.81; p < 0.0001) of cognitive impairment (MCI or AD) as compared to the lowest MeDi score tertile. Among cognitively normal individuals, higher adherence to the MeDi was associated with a reduced risk of MCI (HR = 0.73; 95% CI, 0.56-0.96; p = 0.02) and AD (HR = 0.64; 95% CI, 0.46-0.89; p = 0.007). There was no significant heterogeneity in the analyses. CONCLUSIONS: While the overall number of studies is small, pooled results suggest that a higher adherence to the MeDi is associated with a reduced risk of developing MCI and AD, and a reduced risk of progressing from MCI to AD. Further prospective-cohort studies with longer follow-up and randomized controlled trials are warranted to consolidate the evidence. Systematic review registration number: PROSPERO 2013: CRD42013003868.
BACKGROUND/ OBJECTIVE: To conduct a systematic review of all studies to determine whether there is an association between the Mediterranean diet (MeDi) and cognitive impairment. METHODS: We conducted a comprehensive search of the major databases and hand-searched proceedings of major neurology, psychiatry, and dementia conferences through November 2012. Prospective cohort studies examining the MeDi with longitudinal follow-up of at least 1 year and reporting cognitive outcomes (mild cognitive impairment [MCI] or Alzheimer's disease [AD]) were included. The effect size was estimated as hazard-ratio (HR) with 95% confidence intervals (CIs) using the random-effects model. Heterogeneity was assessed using Cochran's Q-test and I2-statistic. RESULTS: Out of the 664 studies screened, five studies met eligibility criteria. Higher adherence to the MeDi was associated with reduced risk of MCI and AD. The subjects in the highest MeDi tertile had 33% less risk (adjusted HR = 0.67; 95% CI, 0.55-0.81; p < 0.0001) of cognitive impairment (MCI or AD) as compared to the lowest MeDi score tertile. Among cognitively normal individuals, higher adherence to the MeDi was associated with a reduced risk of MCI (HR = 0.73; 95% CI, 0.56-0.96; p = 0.02) and AD (HR = 0.64; 95% CI, 0.46-0.89; p = 0.007). There was no significant heterogeneity in the analyses. CONCLUSIONS: While the overall number of studies is small, pooled results suggest that a higher adherence to the MeDi is associated with a reduced risk of developing MCI and AD, and a reduced risk of progressing from MCI to AD. Further prospective-cohort studies with longer follow-up and randomized controlled trials are warranted to consolidate the evidence. Systematic review registration number: PROSPERO 2013: CRD42013003868.
Authors: W C Willett; F Sacks; A Trichopoulou; G Drescher; A Ferro-Luzzi; E Helsing; D Trichopoulos Journal: Am J Clin Nutr Date: 1995-06 Impact factor: 7.045
Authors: A Trichopoulou; A Kouris-Blazos; M L Wahlqvist; C Gnardellis; P Lagiou; E Polychronopoulos; T Vassilakou; L Lipworth; D Trichopoulos Journal: BMJ Date: 1995-12-02
Authors: Theodora Psaltopoulou; Theodoros N Sergentanis; Demosthenes B Panagiotakos; Ioannis N Sergentanis; Rena Kosti; Nikolaos Scarmeas Journal: Ann Neurol Date: 2013-09-16 Impact factor: 10.422
Authors: John E Morley; John C Morris; Marla Berg-Weger; Soo Borson; Brian D Carpenter; Natalia Del Campo; Bruno Dubois; Keith Fargo; L Jaime Fitten; Joseph H Flaherty; Mary Ganguli; George T Grossberg; Theodore K Malmstrom; Ronald D Petersen; Carroll Rodriguez; Andrew J Saykin; Philip Scheltens; Eric G Tangalos; Joe Verghese; Gordon Wilcock; Bengt Winblad; Jean Woo; Bruno Vellas Journal: J Am Med Dir Assoc Date: 2015-09-01 Impact factor: 4.669
Authors: Maria Vassilaki; Jeremiah A Aakre; Jeremy A Syrjanen; Michelle M Mielke; Yonas E Geda; Walter K Kremers; Mary M Machulda; Rabe E Alhurani; Sara C Staubo; David S Knopman; Ronald C Petersen; Val J Lowe; Clifford R Jack; Rosebud O Roberts Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Claire T McEvoy; Tina Hoang; Stephen Sidney; Lyn M Steffen; David R Jacobs; James M Shikany; John T Wilkins; Kristine Yaffe Journal: Neurology Date: 2019-03-06 Impact factor: 9.910